tiprankstipranks
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX

Vaxcyte (PCVX) Income Statement

176 Followers

Vaxcyte Income Statement

Last quarter (Q1 2024), Vaxcyte's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Vaxcyte's net income was $-95.02M. See Vaxcyte’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 511.32M$ 468.04M$ 232.26M$ 103.67M$ 87.10M$ 53.92M
Operating Income
$ -511.32M$ -468.04M$ -232.26M$ -103.67M$ -87.10M$ -53.92M
Net Non Operating Interest Income Expense
$ 74.18M$ 62.91M$ 8.35M$ 337.00K$ 237.00K$ 592.00K
Other Income Expense
$ -4.79M$ -4.76M$ -1.89M$ -1.59M$ -2.35M$ 3.05M
Pretax Income
$ -286.30M$ -252.27M$ -177.50M$ -100.08M$ -89.22M$ -50.27M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -436.82M$ -402.27M$ -177.50M$ -100.08M$ -89.22M$ -50.27M
Basic EPS
$ -4.22$ -4.14$ -3.44$ -1.93$ -3.02$ -2.56
Diluted EPS
$ -4.22$ -4.14$ -3.44$ -1.93$ -3.02$ -2.56
Basic Average Shares
$ 414.11M$ 97.16M$ 64.88M$ 51.92M$ 29.55M$ 20.86M
Diluted Average Shares
$ 414.11M$ 97.16M$ 64.88M$ 51.92M$ 29.55M$ 20.86M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 511.32M$ 468.04M$ 232.26M$ 103.67M$ 87.10M$ 53.92M
Net Income From Continuing And Discontinued Operation
$ -436.82M$ -402.27M$ -223.49M$ -100.08M$ -89.22M$ -50.27M
Normalized Income
$ -127.19M-$ -139.96M-$ -86.87M$ -50.14M
Interest Expense
----$ 7.00K$ 40.00K
EBIT
$ -456.15M$ -402.27M$ -177.49M$ -100.41M$ -89.21M$ -50.23M
EBITDA
$ -471.65M$ -392.10M$ -169.24M$ -95.55M$ -87.81M$ -49.00M
Currency in USD

Vaxcyte Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis